S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:MDCO - The Medicines Stock Price, Forecast & News

$84.03
-0.04 (-0.05 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$83.99
Now: $84.03
$84.16
50-Day Range
$51.50
MA: $66.79
$84.21
52-Week Range
$16.69
Now: $84.03
$84.48
Volume2.61 million shs
Average Volume2.05 million shs
Market Capitalization$6.70 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.14 million
Book Value($0.30) per share

Profitability

Net Income$-123,160,000.00

Miscellaneous

Employees62
Market Cap$6.70 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.


The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) posted its earnings results on Wednesday, October, 30th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.12. During the same quarter in the prior year, the business earned ($0.70) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

15 brokerages have issued 12 month price targets for The Medicines' shares. Their forecasts range from $49.00 to $145.00. On average, they anticipate The Medicines' share price to reach $75.08 in the next year. This suggests that the stock has a possible downside of 10.7%. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

Has The Medicines been receiving favorable news coverage?

News headlines about MDCO stock have trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. The Medicines earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next few days. View News Stories for The Medicines.

Are investors shorting The Medicines?

The Medicines saw a decline in short interest during the month of November. As of November 29th, there was short interest totalling 23,050,000 shares, a decline of 9.0% from the November 14th total of 25,330,000 shares. Based on an average daily trading volume, of 3,565,600 shares, the short-interest ratio is currently 6.5 days. Currently, 30.1% of the shares of the company are sold short. View The Medicines' Current Options Chain.

Who are some of The Medicines' key competitors?

What other stocks do shareholders of The Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Medicines investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), salesforce.com (CRM), Bank of America (BAC), Celgene (CELG), AT&T (T) and Ionis Pharmaceuticals (IONS).

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Mr. Mark Timney, CEO & Director (Age 54)
  • Mr. Christopher J. Visioli, CFO & Treasurer (Age 43)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 43)
  • Dr. Clive A. Meanwell, Chief Innovation Officer & Director (Age 61)
  • Dr. Goutham Krishna Gorti, VP & Head of Investor Relations

Who are The Medicines' major shareholders?

The Medicines' stock is owned by many different of institutional and retail investors. Top institutional investors include Maverick Capital Ltd. (4.87%), Granahan Investment Management Inc. MA (0.55%), Parametric Portfolio Associates LLC (0.33%), Rhumbline Advisers (0.30%), Silverback Asset Management LLC (0.23%) and Coronation Fund Managers Ltd. (0.21%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Mark Timney, Melvin K Spigelman, Stephen M Rodin and William Crouse. View Institutional Ownership Trends for The Medicines.

Which institutional investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Silverback Asset Management LLC, Rhenman & Partners Asset Management AB, Alberta Investment Management Corp, Creative Planning, Redwood Investment Management LLC, Bailard Inc., Tokio Marine Asset Management Co. Ltd. and Chicago Equity Partners LLC. View Insider Buying and Selling for The Medicines.

Which institutional investors are buying The Medicines stock?

MDCO stock was purchased by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Parametric Portfolio Associates LLC, CIBC Private Wealth Group LLC, First Trust Advisors LP, Coronation Fund Managers Ltd., State of Alaska Department of Revenue and State of Tennessee Treasury Department. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Mark Timney. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $84.03.

How big of a company is The Medicines?

The Medicines has a market capitalization of $6.70 billion and generates $6.14 million in revenue each year. The company earns $-123,160,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. The Medicines employs 62 workers across the globe.View Additional Information About The Medicines.

What is The Medicines' official website?

The official website for The Medicines is http://www.themedicinescompany.com/.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  498 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  861
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel